The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines through pay-for-delay agreements (Lundbeck)

European Commission: Lundbeck and other Pharmaceutical Companies fined for delaying Market Entry of Generic Medicines through pay-for-delay Agreements* On 19 June 2013, the European Commission (the Commission) imposed a fine on the Danish pharmaceutical company Lundbeck and a number of generic companies (notably Merck KGaA/Generics UK (Generics UK is now part of Mylan), Arrow (now part of Actavis), Alpharma (now part of Zoetis), and Ranbaxy) for delaying the market entry of generic citalopram medicines through pay-for-delay agreements. The

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Competition Network Brief, The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines through pay-for-delay agreements (Lundbeck), 19 June 2013, e-Competitions Bulletin June 2013, Art. N° 53279

Visites 583

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues